ANTM (ANTHEM INC COM STK (IN))
Insider Trading Activity
Every open-market purchase and sale reported by ANTM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-13 | Charles Morgan Kendrick JR | EVP & President, Commercial | MIXED | — | — |
| 2022-06-07 | Robert L Dixon JR | Director | Sell | — | — |
| 2022-05-20 | Robert L Dixon JR | Director | A | — | — |
| 2022-05-20 | Bahija Jallal | Director | A | — | — |
| 2022-05-20 | Ryan M. Schneider | Director | A | — | — |
| 2022-05-20 | Elizabeth E Tallett | Director | A | — | — |
| 2022-05-20 | R KERRY CLARK | Director | A | — | — |
| 2022-05-20 | RAMIRO G PERU | Director | MIXED | — | — |
| 2022-05-20 | LEWIS HAY III | Director | A | — | — |
| 2022-05-20 | Susan D. DeVore | Director | A | — | — |
| 2022-05-20 | Antonio F Neri | Director | A | — | — |
| 2022-03-14 | Peter D Haytaian | EVP & Pres., DBG & IngenioRx | MIXED | — | — |
| 2022-03-03 | GAIL BOUDREAUX | President and CEO | MIXED | — | — |
| 2022-03-03 | Felicia F Norwood | EVP & President, GBD | MIXED | — | — |
| 2022-03-03 | Blair Williams Todt | EVP and Chief Legal Officer | MIXED | — | — |
| 2022-03-03 | Peter D Haytaian | EVP & Pres., DBG & IngenioRx | MIXED | — | — |
| 2022-03-03 | Charles Morgan Kendrick JR | EVP & President, Commercial | MIXED | — | — |
| 2022-03-03 | GLORIA M MCCARTHY | EVP & Chief Administrative Off | MIXED | — | — |
| 2022-03-03 | John E Gallina | EVP & Chief Financial Officer | MIXED | — | — |
| 2022-03-03 | Ronald W Penczek | CAO & Controller | MIXED | — | — |
| 2022-02-08 | Ronald W Penczek | CAO & Controller | MIXED | — | — |
| 2022-01-04 | LEAH STARK | EVP & CHRO | F | — | — |
| 2022-01-04 | Felicia F Norwood | EVP & President, GBD | F | — | — |
| 2021-12-03 | Blair Williams Todt | EVP and Chief Legal Officer | F | — | — |
| 2021-11-03 | Charles Morgan Kendrick JR | EVP & President, Commercial | A | — | — |
| 2021-11-03 | Peter D Haytaian | EVP & Pres., DBG & IngenioRx | A | — | — |
| 2021-10-29 | Ronald W Penczek | SVP, Chief Accounting Officer | Sell | — | — |
| 2021-10-04 | Jeffrey D. Alter | EVP, IngenioRx & Anthem Health | F | — | — |
| 2021-09-08 | Prakash R Patel | EVP & President, DBG | F | — | — |
| 2021-09-03 | Susan D. DeVore | Director | A | — | — |
| 2021-07-26 | Ryan M. Schneider | Director | Buy | — | — |
| 2021-07-07 | Felicia F Norwood | EVP & President, GBD | F | — | — |
| 2021-05-28 | Bahija Jallal | Director | A | — | — |
| 2021-05-28 | LEWIS HAY III | Director | A | — | — |
| 2021-05-28 | Elizabeth E Tallett | Director | A | — | — |
| 2021-05-28 | Robert L Dixon JR | Director | A | — | — |
| 2021-05-28 | R KERRY CLARK | Director | A | — | — |
| 2021-05-28 | RAMIRO G PERU | Director | A | — | — |
| 2021-05-28 | Ryan M. Schneider | Director | A | — | — |
| 2021-05-28 | Antonio F Neri | Director | A | — | — |
| 2021-05-26 | John E Gallina | EVP & Chief Financial Officer | MIXED | — | — |
| 2021-05-26 | RAMIRO G PERU | Director | Sell | — | — |
| 2021-05-24 | Robert L Dixon JR | Director | Sell | — | — |
| 2021-05-24 | JULIE A HILL | Director | Sell | — | — |
| 2021-05-07 | Peter D Haytaian | EVP & President, Commercial | Sell | — | — |
| 2021-03-23 | Peter D Haytaian | EVP & President, Commercial | MIXED | — | — |
| 2021-03-08 | Ronald W Penczek | SVP, Chief Accounting Officer | Sell | — | — |
| 2021-03-05 | Ronald W Penczek | SVP, Chief Accounting Officer | Sell | — | — |
| 2021-03-03 | Peter D Haytaian | EVP & President, Commercial | MIXED | — | — |
| 2021-03-03 | Felicia F Norwood | EVP & President, GBD | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President & CEO | 205,854 | — |
| — | EVP & Chief Medical Officer | 110,972 | — |
| — | President and CEO | 94,041 | — |
| — | EVP, Commercial & Specialty | 90,243 | — |
| — | EVP & Chief Financial Officer | 82,126 | — |
| — | EVP & Chief Administrative Off | 60,731 | — |
| — | EVP & Chief Financial Officer | 46,857 | — |
| — | Director | 38,864 | — |
| — | EVP & CEO, IngenioRx | 38,554 | — |
| — | EVP & President, DBG | 36,815 | — |
| — | Director | 31,213 | — |
| — | EVP & Chief HR Officer | 30,323 | — |
| — | EVP & Chief Strategy Officer | 23,249 | — |
| — | EVP & President, GBD | 21,903 | — |
| — | EVP & General Counsel | 17,910 | — |
| — | EVP & President, DBG | 17,230 | — |
| — | EVP & President, Commercial | 15,257 | — |
| — | EVP & Pres., DBG & IngenioRx | 13,441 | — |
| — | EVP & CHRO | 12,403 | — |
| — | Director | 10,395 | — |
| — | Director | 10,061 | — |
| — | Director | 9,491 | — |
| — | Director | 9,446 | — |
| — | Director | 8,194 | — |
| — | Director | 5,154 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANTM quote page; the site-wide leaderboard is on the insider transactions hub.